alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
MEDICATION TRACKER

3 Months of Daily Isoniazid Plus Rifampin (3HR) for Latent Tuberculosis (TB) Infection

Patient Name:

Your Medication Schedule (Providers: Indicate the appropriate number of pills)

Medicine Number of pills per dose Frequency Duration Doses

Isoniazid: mg 

Rifampin: mg

TOTAL:

Isoniazid:

Rifampin:

Once a day 3 months 90

Normal Side Effects

Most people can take their TB medicines without any problems. The rifampin medicine may cause your urine (pee), saliva, tears, 

or sweat to appear an orange-red color. This is normal and the color may fade over time. When taking isoniazid, your doctor may 

have you take vitamin B6 with your medication.

STOP taking your medicine and CALL your TB doctor or nurse right away if you have:

■ Less appetite, or no appetite for food

■ An upset stomach or stomach cramps

■ Nausea or vomiting

■ Severe diarrhea or light-colored stools (poop)

■ Brown, tea-colored, or cola-colored urine

■ Easy bruising or bleeding

■ Rash or itching

■ Yellowing skin or eyes

■ Severe weakness or tiredness

■ Fever

■ Head or body aches

■ Dizziness

■ Tingling or numbness in 

your hands or feet

Please talk to your doctor or nurse if you have any questions or concerns about treatment for latent TB infection.

Doctor/Clinic Contact Information

Name of the staff caring for you: Phone:

Address: Hours: 

Keeping Track of Your Treatment

On the table below, check the box and write the date to show when you took your medicine. 

Doses 1–30

Dose # Taken? Date

1

2

3

4

5

6

7

8

9

10

Dose # Taken? Date

11

12

13

14

15

16

17

18

19

20

Dose # Taken? Date

21

22

23

24

25

26

27

28

29

30
Doses 31–60

Dose # Taken? Date

31

32

33

34

35

36

37

38

39

40

Dose # Taken? Date

41

42

43

44

45

46

47

48

49

50

Dose # Taken? Date

51

52

53

54

55

56

57

58

59

60

Doses 61–90

Dose # Taken? Date

61

62

63

64

65

66

67

68

69

70

Dose # Taken? Date

71

72

73

74

75

76

77

78

79

80

Dose # Taken? Date

81

82

83

84

85

86

87

88

89

90

www.cdc.gov/tb

 CS330204-A
No. 10-511.

#### Harry R. Jackson, et al., Petitioners v. District of Columbia Board of Elections and Ethics, et al.

562 U.S. 1178, 131 S. Ct. 1001,

178 L. Ed. 2d 827,

2011 U.S. LEXIS 730.

January 18, 2011.

Petition for writ of certiorari to the District of Columbia Court of Appeals denied.

Same case below, 999 A.2d 89.
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                         JAN-31-1998
<PERIOD-END>                              JAN-31-1998
<CASH>                                      5,113,000
<SECURITIES>                               10,349,000
<RECEIVABLES>                              11,819,000
<ALLOWANCES>                                1,032,698
<INVENTORY>                                83,841,000
<CURRENT-ASSETS>                          112,717,000 
<PP&E>                                    269,723,163
<DEPRECIATION>                            156,598,983
<TOTAL-ASSETS>                            261,624,000
<CURRENT-LIABILITIES>                      99,769,000
<BONDS>                                   100,000,000
<PREFERRED-MANDATORY>                               0
<PREFERRED>                                         0
<COMMON>                                      115,000
<OTHER-SE>                                 32,122,000
<TOTAL-LIABILITY-AND-EQUITY>              261,624,000
<SALES>                                   967,090,000 
<TOTAL-REVENUES>                          967,090,000
<CGS>                                     723,446,000         
<TOTAL-COSTS>                             723,446,000 
<OTHER-EXPENSES>                                    0
<LOSS-PROVISION>                               85,000
<INTEREST-EXPENSE>                         11,751,000
<INCOME-PRETAX>                             4,692,000
<INCOME-TAX>                                (400,000)
<INCOME-CONTINUING>                         5,092,000
<DISCONTINUED>                                      0 
<EXTRAORDINARY>                                     0
<CHANGES>                                           0 
<NET-INCOME>                                5,092,000        
<EPS-PRIMARY>                                    0.47
<EPS-DILUTED>                                    0.45
        


</TABLE>
LIST OF SUCCESSFUL BIDDERS

DATE: 3/16/2015 PAGE: 001

IFB NUMBER: 39-4604

IFB ITEM SALE: BAHRAIN METALLIC & NON-METALLIC SCRAP

SCO: WILLIE N. PAYNE

 

BID OPENING DATE: 12/18/2014

----------------------------------------------------------------------------

BIDDER NAME

------------------------------------------------------------------------ ITEM

NO

U/I ITEM NAME UNIT BID

PRICE

------------------------------------------------------------------------

------------------------------------------------------------------------

AL-BAZ 2000 GEN TRAD & CONT. CO.

0001 LB MIXED METALS SCRAP WITH 

DEMILITARIZATION AND/OR MUTILATION 

PERFORMED BY THE USG.

$0.320

CLASS WORLDWIDE GENERAL TRADING LCC

0001 LB MIXED METALS SCRAP WITH 

DEMILITARIZATION AND/OR MUTILATION 

PERFORMED BY THE USG.

$0.300

------------------------------------------------------------------------

------------------------------------------------------------------------

WAHIDULLAH AHMADZAI GROUP LTD

0002 LB ELECTRONIC SCRAP WITH DEMILITARIZATION 

AND/OR MUTILATION PERFORMED BY THE 

USG.

$0.480

------------------------------------------------------------------------

------------------------------------------------------------------------
<PAGE>
                                                                      EXHIBIT 23



                        INDEPENDENT ACCOUNTANTS' CONSENT


The Board of Directors
Claire's Stores, Inc.:


We consent to incorporation by reference in the registration statement on Form
S-3 (No. 333-58549) and Form S-8 (No. 333-42027) of Claire's Stores, Inc. of our
report dated March 8, 2004, relating to the consolidated balance sheets of
Claire's Stores, Inc. and subsidiaries as of January 31, 2004 and February 1,
2003, and the related consolidated statements of operations and comprehensive
income, changes in stockholders' equity, and cash flows for the fiscal years
ended January 31, 2004, February 1, 2003, and February 2, 2002, which report
appears in the January 31, 2004 annual report on Form 10-K of Claire's Stores,
Inc.

Our report refers to a change in method of accounting for goodwill and
intangible assets in the fiscal year ended January 31, 2003.


/s/ KPMG LLP


Fort Lauderdale, Florida
April 13, 2004
a4
VY
=
Cc
2
~~
©
.N
c
>
£
=
~
c
£
£
ro)
Cc
2
~~
©
Zz
No. 10-10506.

#### Mondrea Vinning, Petitioner v. Illinois.

565 U.S. 839, 132 S. Ct. 147,

181 L. Ed. 2d 65,

2011 U.S. LEXIS 6033.

October 3, 2011.

Petition for writ of certiorari to the Appellate Court of Illinois, First District, denied.

Same case below, 404 Ill. App. 3d 1171, 374 Ill. Dec. 1079, 996 N.E.2d 774.
Final - August 30, 2021

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

PRESIDER/PRESENTER(s)

Dr. Grace Lee (ACIP Chair)

Dr. Amanda Cohn (ACIP Executive Secretary, CDC)

10:15 Coronavirus Disease 2019 (COVID-19) Vaccines

Introduction

BNT-162b2 COVID-19 vaccine BLA safety and efficacy data 

Dr. Matthew Daley (ACIP, WG Chair)

Dr. John Perez (Pfizer-BioNTech)

11:00 Break

11:15 Public Comment

11:45 Break

12:00 Safety update for COVID-19 vaccines: VAERS

Safety update for COVID-19 vaccines: VSD

VaST assessement 

Benefit-risk discussion for use of Pfizer-BioNTech COVID-19 vaccine in individuals 

≥16 years of age

Dr. John Su (CDC/NCEZID)

Dr. Nicola Klein (Kaiser Permanente Northern California)

Dr. Grace Lee (ACIP, VaST Co-chair)

Dr. Hannah Rosenblum (CDC/NCIRD)

1:30 Break

1:45 GRADE: Pfizer/BioNTech COVID-19 vaccine 

Evidence to Recommendations Framework: Pfizer-BioNTech COVID-19 vaccine

Dr. Julia Gargano (CDC/NCIRD)

Dr. Kathleen Dooling (CDC/NCIRD)

2:45 Break

3:00 Discussion

VOTE

Pfizer/BioNTech COVID-19 vaccine for individuals ≥16 years of age Dr. Kathleen Dooling (CDC/NCIRD)

3:30 Break

3:45 Framework for COVID-19 booster doses

Discussion

Dr. Sara Oliver (CDC/NCIRD)

4:30 Adjourn

Acronyms

CDC Centers for Disease Control and Prevention

CMS Centers for Medicare and Medicaid Services 

COVID-19 Coronavirus disease 2019

EtR Evidence to Recommendations Framework

FDA Food and Drug Administration

GRADE Grading of Recommendations Assessment, Development and Evaluation

HRSA Health Resources and Services Administration

IHS Indian Health Service

NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID] 

NCIRD National Center for Immunization & Respiratory Diseases [of CDC/OID] 

NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/OID]

NIAID National Institute of Allergy and Infectious Diseases

OIDP Office of Infectious Disease and HIV/AIDS Policy

SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2

WG Work Group

WHO World Health Organization

VE Vaccine Effectiveness

Monday, August 30, 2021

10:00 Welcome & Introductions

Centers for Disease Control and Prevention

Atlanta, Georgia 30329 

August 30, 2021

AGENDA ITEM

page 1 of 1
ATTORNEY GRIEVANCE COMMISSION * IN THE 

OF MARYLAND

* COURT OF APPEALS

v. * OF MARYLAND

* Misc. Docket AG No. 59

September Term, 2019

JONATHAN FREDERICK SEAMON LOVE *

(No. 477489-V, Circuit Court

* for Montgomery County)

CORRECTED ORDER

Upon consideration of the Joint Petition for Indefinite Suspension with the Right to 

Petition for Reinstatement after 90 Days filed by the Attorney Grievance Commission of 

Maryland and the Respondent, Jonathan Frederick Seamon Love, it is this 11th day of January,

2021

ORDERED, by the Court of Appeals of Maryland, that the Respondent, Jonathan 

Frederick Seamon Love, be indefinitely suspended from the practice of law in the State of 

Maryland, effective February 19, 2021, with the right to petition for reinstatement after 90 days,

for engaging in professional misconduct that violated Rules 1.1, 1.3, 1.4, 1.5, 1.15(a) and 8.4(a)

and (d) of the Rules of Professional Conduct; and it is further

ORDERED, that, effective February 19, 2021, the Clerk of this Court shall remove the 

name of Jonathan Frederick Seamon Love from the register of attorneys in this Court, and certify 

that fact to the Trustees of the Client Protection Fund of the Bar of Maryland and all Clerks of all 

judicial tribunals in this State in accordance with Maryland Rule 19-761.

 /s/ Mary Ellen Barbera

Chief Judge
The correction notice(s) for this opinion(s) can be found here: 

https://mdcourts.gov/sites/default/files/import/appellate/correctionnotices/coa/59a19agcn.pdf
No. 11-5955.

#### Shawn Kearns, Petitioner v. United States.

565 U.S. 925, 132 S. Ct. 358,

181 L. Ed. 2d 226,

2011 U.S. LEXIS 7082.

October 3, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.

Same case below, 429 Fed. Appx. 350.
No. 11-5813.

#### Manivone Saignaphone, Petitioner v. United States.

565 U.S. 922, 132 S. Ct. 349,

181 L. Ed. 2d 220,

2011 U.S. LEXIS 6870.

October 3, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Tenth Circuit denied.

Same case below, 423 Fed. Appx. 821.
I 

116TH CONGRESS 

1ST SESSION H. R. 318 

To reauthorize the National Geologic Mapping Act of 1992. 

IN THE HOUSE OF REPRESENTATIVES 

JANUARY 8, 2019 

Mr. LAMBORN (for himself and Mr. BROWN of Maryland) introduced the 

following bill; which was referred to the Committee on Natural Resources 

A BILL 

To reauthorize the National Geologic Mapping Act of 1992. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘National Geologic 

5 Mapping Act Reauthorization Act’’. 

6 SEC. 2. REAUTHORIZATION OF NATIONAL GEOLOGIC MAP7 PING ACT OF 1992. 

8 (a) REAUTHORIZATION.— 

9 (1) IN GENERAL.—Section 9(a) of the National 

10 Geologic Mapping Act of 1992 (43 U.S.C. 31h(a)) 

11 is amended by striking ‘‘2018’’ and inserting 

12 ‘‘2023’’. 


pamtmann on DSKBFK8HB2PROD with BILLS
2 

•HR 318 IH

1 (2) CONFORMING AMENDMENT.—Section 

2 4(b)(1) of the National Geologic Mapping Act of 

3 1992 (43 U.S.C. 31c(b)(1)) is amended by striking 

4 ‘‘Omnibus Public Land Management Act of 2009’’ 

5 each place it appears in subparagraphs (A) and (B) 

6 and inserting ‘‘National Geologic Mapping Act Re7 authorization Act’’. 

8 (b) GEOLOGIC MAPPING ADVISORY COMMITTEE.— 

9 Section 5(a)(3) of the National Geologic Mapping Act of 

10 1992 (43 U.S.C. 31d(a)(3)) is amended by striking ‘‘Asso11 ciate Director for Geology’’ and inserting ‘‘Associate Di12 rector for Core Science Systems’’. 

13 (c) CLERICAL AMENDMENTS.—Section 3 of the Na14 tional Geologic Mapping Act of 1992 (43 U.S.C. 31b) is 

15 amended— 

16 (1) in paragraph (4), by striking ‘‘section 

17 6(d)(3)’’ and inserting ‘‘section 4(d)(3)’’; 

18 (2) in paragraph (5), by striking ‘‘section 

19 6(d)(1)’’ and inserting ‘‘section 4(d)(1)’’; and 

20 (3) in paragraph (9), by striking ‘‘section 

21 6(d)(2)’’ and inserting ‘‘section 4(d)(2)’’. 

Æ 


pamtmann on DSKBFK8HB2PROD with BILLS
I 

116TH CONGRESS 

1ST SESSION H. R. 3172 

To prohibit the manufacture for sale, offer for sale, distribution in commerce, 

or importation into the United States of any inclined sleeper for infants, 

and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

JUNE 10, 2019 

Mr. CA ́RDENAS introduced the following bill; which was referred to the 

Committee on Energy and Commerce 

A BILL 

To prohibit the manufacture for sale, offer for sale, distribution in commerce, or importation into the United States 

of any inclined sleeper for infants, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Safe Sleep Act of 

5 2019’’. 


kjohnson on DSK79L0C42 with BILLS
2 

•HR 3172 IH

1 SEC. 2. PROHIBITION ON SALE OF INCLINED SLEEPERS 

2 FOR INFANTS. 

3 (a) PROHIBITION ON THE SALE OF INCLINED SLEEP4 ERS FOR INFANTS.—Beginning on the date that is 180 

5 days after the date of enactment of this Act, it shall be 

6 unlawful for any person to manufacture for sale, offer for 

7 sale, distribute in commerce, or import into the United 

8 States any inclined sleeper for infants. 

9 (b) TREATMENT OF VIOLATION.—A violation of sub10 section (a) shall be treated as a violation of section 

11 19(a)(1) of the Consumer Product Safety Act (15 U.S.C. 

12 2068(a)(1)). 

13 (c) INCLINED SLEEPER FOR INFANTS DEFINED.—In 

14 this section, the term ‘‘inclined sleeper for infants’’ means 

15 a product with an inclined sleep surface greater than ten 

16 degrees that is intended, marketed, or designed to provide 

17 sleeping accommodations for an infant up to one year old. 

Æ 


kjohnson on DSK79L0C42 with BILLS
Plan de acción de 

MisMedicamentos 

El plan de acción de MisMedicamentos es una herramienta que 

puede usar con su proveedor de atención médica (p. ej., médico, 

farmacéutico, personal de enfermería, profesional en enfermería 

superior o asociado médico) para ayudarle a identifcar los 

medicamentos que pueden aumentar su riesgo de caídas o choque 

automovilísticos. Su proveedor de atención médica puede ayudarle 

a hacer un plan para ajustar sus medicamentos si es necesario. 

Cómo usar el plan de acción de MisMedicamentos: 

Lleve este plan de acción y su lista de MisMedicamentos cada vez que reciba atención médica 

o vaya a la farmacia. Pídale a su proveedor de atención médica que revise la lista con usted. 

Esto le ayudará a usted a saber sobre cada medicamento que toma, por qué lo toma y si aún 

lo necesita. 

Su proveedor de atención médica puede: 

1. Identifcar todos los medicamentos 

que toma y que puedan tener efectos 

secundarios que afecten su riesgo 

de caídas o su capacidad para 

conducir de manera segura. Esto 

incluye medicamentos recetados, 

de venta libre (OTC, por sus siglas 

en inglés), vitaminas, suplementos 

o productos herbales. Esto puede 

incluir medicamentos o suplementos 

que puedan tener interacciones. 

2. Hablar sobre la posibilidad de ajustar 

cualquiera de los medicamentos o 

suplementos identifcados para 

reducir su riesgo de caídas y de 

choques automovilísticos. 

Recuerde hablar con su 

proveedor de atención 

médica antes de suspender 

o cambiar los medicamentos 

que tome. 

Pasos para usted: 

1. En la siguiente página podrá encontrar 

preguntas que le puede hacer a su 

proveedor de atención médica sobre sus 

medicamentos o suplementos. 

2. Complete la tabla en la siguiente página 

mientras está con su proveedor de 

atención médica. 

3. Recuerde actualizar la lista de 

MisMedicamentos con cualquier cambio 

que usted y su proveedor de atención 

médica hayan realizado. 

Mi nombre: _________________ Fecha de preparación: _________ 

Proveedor de atención médica: _____________________________ 

Tel. del proveedor: ________________________________________ 

Fecha y hora de la cita de seguimiento: _______________________ 
Cambios en medicamentos 

Cómo cambiaremos este medicamento 

Por qué estamos haciendo este cambio 

Fecha en que se hizo el cambio 

a hacerle a mi proveedor de atención médica sobre mis medicamentos 

 benefcios o los riesgos de 

biar o reducir el medicamento? 

 benefcios o los riesgos de seguir 

dicamento? 

ecundarios pueden ocurrir si cambio 

e tomo el medicamento? 

• ¿Cuáles son las medidas que debo tomar para 

ajustar mi medicamento, si es necesario? 

• ¿De qué otras formas puedo ayudar a controlar la 

enfermedad para la que tomo el medicamento? (Por ejemplo, ¿hay otro medicamento o cambio de comportamiento que pueda probar?) 

, visite: bit.ly/Medicines-Risk 

MLS-328765 | 2023
# C_2016098EN.01001301.xml

| 14.3.2016 | EN | Official Journal of the European Union | C 98/13 |
| --- | --- | --- | --- |

14.3.2016

EN

Official Journal of the European Union

C 98/13

---

Judgment of the Court (Fourth Chamber) of 21 January 2016 (request for a preliminary ruling from the Verwaltungsgerichtshof — Austria) — Vorarlberger Gebietskrankenkasse, Alfred Knauer v Landeshauptmann von Vorarlberg

(Case C-453/14) (1)

1

((Reference for a preliminary ruling - Regulation (EC) No 883/2004 - Article 5 - Meaning of ‘equivalent benefits’ - Equal treatment of old-age benefits of two Member States of the European Economic Area - National legislation taking into account old-age benefits received in other Member States for the purpose of calculating social security contributions))

(2016/C 098/15)

Language of the case: German

Referring court

Referring court

Verwaltungsgerichtshof

Parties to the main proceedings

Parties to the main proceedings

Appellants: Vorarlberger Gebietskrankenkasse, Alfred Knauer

Appellants:

Respondent: Landeshauptmann von Vorarlberg

Respondent:

Other party to the proceedings: Rudolf Mathis

Other party to the proceedings:

Operative part of the judgment

Operative part of the judgment

Article 5(a) of Regulation (EC) No 883/2004 of the European Parliament and of the Council of 29 April 2004 on the coordination of social security systems must be interpreted as meaning that, in circumstances such as those at issue in the main proceedings, old-age benefits provided under an occupational pension scheme of one Member State and those provided under a statutory pension scheme of another Member State — both schemes being within the scope of that regulation — are equivalent benefits within the meaning of that provision, where both categories of benefits have the same aim of ensuring that their recipients maintain a standard of living commensurate with that which they enjoyed prior to retirement.

---

(1)  OJ C 462, 22.12.2014.

1

---
IN THE COURT OF CRIMINAL APPEALS

OF TEXAS

NO. WR-85,315-01

EX PARTE JOHNATHAN JEROID JOHNSON, Applicant

ON APPLICATION FOR A WRIT OF HABEAS CORPUS

CAUSE NO. 1316114-A IN THE 232 DISTRICT COURT ND

FROM HARRIS COUNTY

Per curiam.

O P I N I O N

Pursuant to the provisions of Article 11.07 of the Texas Code of Criminal Procedure, the

clerk of the trial court transmitted to this Court this application for a writ of habeas corpus. Ex parte

Young, 418 S.W.2d 824, 826 (Tex. Crim. App. 1967). Applicant pleaded guilty to possession of a

controlled substance and was sentenced to two years’ imprisonment. He did not appeal his

conviction. 

Applicant contends that his plea was involuntary and that his conviction violates due process

because after he entered his plea, the evidence in his case was tested and found not to contain any

controlled substance or dangerous drug. Although Applicant has discharged his sentence in this
case, he alleges that he is suffering continuing consequences as a result of this conviction. Those

continuing consequences are sufficient to allow this Court to address his claims. Ex parte

Harrington, 310 S.W.3d 452, 456-57 (Tex. Crim. App. 2010).

The parties have entered agreed findings of fact and conclusions of law, and the trial court

has determined that Applicant’s decision to plead guilty in this case was not a voluntary and

intelligent choice. Applicant is entitled to relief. Ex parte Mable, 443 S.W.3d 129 (Tex. Crim. App.

2014).

Relief is granted. The judgment in Cause No. 131611401010 in the 232 District Court of nd

Harris County is set aside.

Copies of this opinion shall be sent to the Texas Department of CriminalJustice–Correctional

Institutions Division and Pardons and Paroles Division.

Delivered: June 27, 2016

Do not publish
DLA Distribution Europe

Lt. Col. Kimberly Rembert

United States Army

Commander

Army Lt. Col. Kimberly Rembert, a native of Pensacola, Florida, took command 

of Defense Logistics Agency Distribution Europe July 6, 2022. She graduated 

with a Bachelor of Science in Biology from Florida Agricultural and Mechanical 

University and was commissioned a second lieutenant in the Ordnance Corps, 

in 2004. Rembert also holds a Masters of Science in Logistics and Supply Chain 

Management from Embry Riddle Aeronautical University. 

Her previous assignments include: maintenance control officer, Golf Forward 

Support Company, 3rd Battalion, 16th Field Artillery Regiment; 2nd Brigade 

Combat Team, 4th Infantry Division; supply officer, 704th Brigade Support 

Battalion, 4th Brigade Combat Team, 4th Infantry Division; support 

operations planner and brigade maintenance officer, 27th Brigade Support Battalion, 4th Brigade Combat Team, 

1st Calvary Division, Fort Hood, Texas; SPO logistics operations officer, SPO transportation operations officer, 3rd 

Sustainment Brigade; commander, 632nd Maintenance Company, 87th Combat Sustainment Support Battalion, 

3rd Sustainment Brigade, Fort Stewart, Georgia; support operations observer, controller, trainer, Adler Team; 

transportation operations planner, Joint Multinational Readiness Center, Hohenfels, Germany; Brigade Logistics 

Support Team, Army Field Support Battalion-Bliss; executive officer, 501st Brigade Support Battalion, 1st Stryker 

Brigade Combat Team, 1st Armored Division, Fort Bliss, Texas; logistics and strategic planner, Plans and Policy 

Directorate, US Army Central, Shaw Air Force Base, Sumter, South Carolina and most recently as the plans branch 

chief for the J4, NATO Rapid Deployable Corps-Italy in Milan, Italy. 

Rembert deployed three times in support of Operation Iraqi Freedom. 

She is a graduate of the Ordnance Officer Basic Course, Aberdeen Proving Ground, Maryland; Combined Logistics 

Captains Career Course, Fort Gregg-Adams, Virginia; Command and General Staff College at Fort Leavenworth, 

Kansas. 

Rembert’s awards and decorations include the Bronze Star Medal, Defense Meritorious Servic Medal, Meritorious 

Service Medal (three oak leaf clusters,) Army Commendation Medal (two oak leaf clusters,) Army Achievement 

Medal (two oak leaf clusters,) Combat Action Badge and Ordnance Order of Samuel Sharp.